Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 21:04:39时区推断·⟳ 抓取 21:06:14·⚡ 决策 08-03 21:18:42 +12m28s·85.0 天前
GE HealthCare推出Invenia ABUS Prime并获FDA/CE相关准入
新系统用于致密乳腺补充筛查，披露40%女性致密乳腺、读片时间降低33%、最高93%灵敏度等产品指标。
📄 原文Investing.com↗ 原文
GE HealthCare launches automated breast ultrasound system
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks CHICAGO - GE HealthCare announced the launch of…
不做 GE HealthCare（GEHC.US）
常规产品发布和准入，未披露订单或收入增量，相对206亿美元业务体量太小，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 媒体转述GE HealthCare新闻稿，确认FDA/CE相关准入和产品发布。
关键理由
- 新系统用于致密乳腺补充筛查，披露40%女性致密乳腺、读片时间降低33%、最高93%灵敏度等产品指标。
- 但GE HealthCare自身披露为206亿美元收入规模，本次未披露订单、价格、装机目标或收入增量，短线难形成市值级重定价。
主要风险
- 产品发布和510(k)/CE准入更像产品线迭代，商业化节奏和装机转化未量化。
工具调用 · 历史记录,结果未知(5 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- validate_order · 结果未知
- event_study · 结果未知
原文全文
展开原文 · 1,969 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
CHICAGO - GE HealthCare announced the launch of Invenia ABUS Prime and ABUS StreamVue, a browser-based reading solution that received U.S. Food and Drug Administration 510(k) clearance and CE Marking, according to a press release statement.
The Invenia ABUS Prime system is designed for supplemental screening of women with dense breasts. Studies show 40% of women have dense breasts, which can make cancers harder to detect on mammography. Research indicates mammography may miss one-third of cancers in dense breasts.
The system features cSound Imageformer with AI-enabled tools including Scan Quality Assessment and Auto Nipple Detection. A Fast Scan tool increases scan speed by up to 40% compared to Invenia ABUS 2.0. The AI Assistant powered by QVCAD demonstrated a 33% reduction in reading time and up to 93% sensitivity for lesion detection in studies.
ABUS StreamVue is a zero-footprint, browser-based reading solution designed to enable remote exam review across enterprise imaging networks. GE HealthCare is collaborating with Candelis, Inc. to deliver the technology.
BeSound in Los Angeles is among the first U.S. installations of Invenia ABUS Prime. The facility plans to launch a mobile screening unit to expand access to supplemental breast cancer screening.
"At BeSound, our mission is to make supplemental breast screening more accessible and more convenient for the women who need it," said Bailey Renger, Founder and CEO of BeSound.
Invenia ABUS Prime is U.S. FDA Premarket approved and CE Marked. ABUS StreamVue is U.S. FDA 510(k) cleared and CE Marked. Availability is subject to local regulatory approvals and may vary by country.
GE HealthCare is a $20.6 billion business with approximately 54,000 employees providing medical technology and healthcare solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CHICAGO - GE HealthCare announced the launch of Invenia ABUS Prime and ABUS StreamVue, a browser-based reading solution that received U.S. Food and Drug Administration 510(k) clearance and CE Marking, according to a press release statement.
The Invenia ABUS Prime system is designed for supplemental screening of women with dense breasts. Studies show 40% of women have dense breasts, which can make cancers harder to detect on mammography. Research indicates mammography may miss one-third of cancers in dense breasts.
The system features cSound Imageformer with AI-enabled tools including Scan Quality Assessment and Auto Nipple Detection. A Fast Scan tool increases scan speed by up to 40% compared to Invenia ABUS 2.0. The AI Assistant powered by QVCAD demonstrated a 33% reduction in reading time and up to 93% sensitivity for lesion detection in studies.
ABUS StreamVue is a zero-footprint, browser-based reading solution designed to enable remote exam review across enterprise imaging networks. GE HealthCare is collaborating with Candelis, Inc. to deliver the technology.
BeSound in Los Angeles is among the first U.S. installations of Invenia ABUS Prime. The facility plans to launch a mobile screening unit to expand access to supplemental breast cancer screening.
"At BeSound, our mission is to make supplemental breast screening more accessible and more convenient for the women who need it," said Bailey Renger, Founder and CEO of BeSound.
Invenia ABUS Prime is U.S. FDA Premarket approved and CE Marked. ABUS StreamVue is U.S. FDA 510(k) cleared and CE Marked. Availability is subject to local regulatory approvals and may vary by country.
GE HealthCare is a $20.6 billion business with approximately 54,000 employees providing medical technology and healthcare solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。